Skip to main content
Clinical Trials/NCT02871115
NCT02871115
Completed
Not Applicable

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

Massachusetts General Hospital1 site in 1 country62 target enrollmentJanuary 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Massachusetts General Hospital
Enrollment
62
Locations
1
Primary Endpoint
Rates of study enrollment
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer. The sponsor of this protocol is the Massachusetts General Hospital Cancer Center who is providing funding for this research study.

Detailed Description

The goals of the proposed study are: (1) to demonstrate the feasibility and acceptability of delivering PRIME (Pharmacist Reconciliation to Improve Medication Management in the Elderly) to older patients with breast, gastrointestinal, and lung cancers; and (2) to estimate the effect size (i.e. the magnitude of the difference between groups) of PRIME for improving medication management (e.g. accurate medication list, less polypharmacy, fewer potentially inappropriate medications) and achieving up-to-date vaccinations.

Registry
clinicaltrials.gov
Start Date
January 2017
End Date
April 14, 2018
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ryan Nipp

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 65 or older
  • Diagnosed with any stage breast, GI or lung cancer
  • Panning to receive first-line chemotherapy at MGH
  • Verbal fluency in English

Exclusion Criteria

  • Unwilling or unable to participate in the study
  • Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes prohibits informed consent or participation in the study

Outcomes

Primary Outcomes

Rates of study enrollment

Time Frame: 2 years

To determine rates of study enrollment, we will assess the proportion of eligible patients who enroll in the study.

Secondary Outcomes

  • Rates of Study Completion(2 years)
  • Number Of Medications(Baseline to 4 weeks)
  • Rates of Polypharmacy(Baseline to 4 weeks)
  • Change In The Number Of Potentially Inappropriate Medications(Baseline to 4 weeks)
  • Number Of Potentially Inappropriate Medications(Baseline to 4 weeks)
  • Rates Of Appropriate Pneumococcal Vaccinations(Baseline to 8 weeks)
  • Rates Of Appropriate Influenza Vaccinations(Baseline to 8 weeks)
  • Rates of study satisfaction(2 years)
  • Rates of Medication List Accuracy(Baseline to 4 weeks)
  • Change In The Number Of Medications(Baseline to 4 weeks)

Study Sites (1)

Loading locations...

Similar Trials